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Background: The intracellular deposition of misfolded proteins is a common neuropathological hallmark of most
neurodegenerative disorders. Increasing evidence suggests that these pathogenic proteins may spread to
neighboring cells and induce the propagation of neurodegeneration.
Results: In this study, we have demonstrated that α-synuclein (αSYN), a major constituent of intracellular
inclusions in synucleinopathies, was taken up by neuronal and oligodendroglial cells in both a time- and
concentration-dependent manner. Once incorporated, the extracellular αSYN was immediately assembled into
high-molecular-weight oligomers and subsequently formed cytoplasmic inclusion bodies. Furthermore, αSYN uptake by
neurons and cells of the oligodendroglial lineage wasmarkedly decreased by the genetic suppression and pharmacological
inhibition of the dynamin GTPases, suggesting the involvement of the endocytic pathway in this process.
Conclusions:Our findings shed light on themode of αSYN uptake by neuronal and oligodendroglial cells and identify
therapeutic strategies aimed at reducing the propagation of proteinmisfolding.
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Lewy bodies (LBs), which are the cardinal histological hall-
mark of Parkinson’s disease (PD), contain abnormal fila-
mentous α-synuclein (αSYN) aggregates. In addition, a
variety of other neurodegenerative diseases are associated
with αSYN-positive lesions [1,2]. The presence of αSYN in
LBs, Lewy neurites or glial cytoplasmic inclusions (GCIs)
in PD and related disorders provides a conceptual link
that has led to the use of the term ‘synucleinopathy’ to en-
compass these diseases [3-5]. Emerging evidence from
genetic and biochemical studies demonstrates that abnor-
mal αSYN aggregates directly contribute to neurodegen-
eration in PD and other synucleinopathies [6-10]. Because* Correspondence: thasegawa@med.tohoku.ac.jp
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reproduction in any medium, provided the orαSYN is enriched in the presynaptic nerve terminals and
is mainly detected in the cytosolic and synaptosomal frac-
tions, it has long been believed that αSYN exerts its
physiological as well as pathogenic effects intracellularly
[11,12]. However, accumulating evidence suggests that
both monomeric and oligomeric αSYN can be secreted
into the extracellular milieu, thereby affecting the normal
physiological state of neighboring cells [13-17]. For ex-
ample, in vitro-generated soluble αSYN oligomers can in-
duce the transmembrane seeding of αSYN aggregation
and can eventually lead to cell death [18,19]. Moreover,
exogenous αSYN fibrils have been shown to induce peri-
karyal LB pathology, which can lead to synaptic dysfunc-
tion and neuronal cell death [20]. The existence of the
transcellular spread of αSYN has also been verified by co-
culture experiments and in vivo animal models, which
showed that αSYN aggregates released from neuronal cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bodies [21-23]. Finally, the existence of an in vivo intercel-
lular propagation of αSYN aggregates was supported by
recent observations of LB-like inclusions in the grafted
neurons of PD patients who had received transplants of
fetal mesencephalic neurons more than a decade previ-
ously [24-26]. In addition to PD, the intercellular trans-
mission of αSYN pathology can be assumed to be present
in multiple system atrophy (MSA), in which widespread
αSYN-positive GCIs are found in oligodendroglia, a type
of brain cell that does not normally express αSYN [27-29].
Phenomenologically, the propagation theory is also at-
tractive as an explanation for the hierarchical distribution
of Lewy pathology in PD, a theory proposed by Braak and
colleagues [30]. To understand how αSYN travels from
cell to cell, the underlying mechanisms responsible for
αSYN uptake and secretion must be elucidated. In this
study, we provide evidence to support the functional role
of dynamin-mediated endocytosis in the process of αSYN
uptake by neurons and oligodendroglial cells. Further-
more, we propose therapeutic strategies aimed at reducing
the propagation of protein misfolding in synucleinopathies.
Results
The characterization of recombinant α-synuclein
Ectopically expressed proteins were collected from crude
bacterial lysates and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed
by Coomassie brilliant blue (CBB) staining and immuno-
blotting with an anti-αSYN antibody (Ab). Upon isopro-
pyl β-D-1-thiogalactopyranoside (IPTG) induction, the
BL21(DE3)pLysS E. coli was transformed with pGEX6P-
1/αSYN, which produced a GST-αSYN fusion protein
that migrated at 44 kDa under denaturing conditions
(Figure 1A, asterisk). After enzymatic removal of the
GST-tag, monomeric αSYN was detected at a molecular
mass of approximately 18 kDa, which was larger than
the predicted value of 14 kDa (Figure 1A (a), arrow-
head). Immunoblot analysis, using the anti-GST anti-
body, did not detect any remaining GST-αSYN after the
removal of the GST moiety. The slow gel mobility may
be attributed to the weak binding of SDS due to the
highly acidic C-terminal sequence of αSYN [31]. How-
ever, under native conditions, the majority of the recom-
binant αSYN migrated to a position corresponding to
approximately 54 kDa, which was assumed to be com-
posed mainly of trimers as well as a few monomers and
oligomers/multimers (Figure 1A (b)). It is important to
note that the recombinant αSYN did not self-assemble
into SDS-resistant, soluble oligomers after 24 hours at
37°C in the cell-free culture medium (Figure 1A (c)).
There was no visible band in the PBS washing buffer
that flowed through the column, as revealed by CBB
staining and αSYN immunoblotting (data not shown).Extracellular α-synuclein was incorporated and assembled
into oligomers in neuronal and oligodendroglial cells
To elucidate how αSYN is internalized into cells, human
SH-SY5Y neuronal and KG1C oligodendroglial cells
[32,33] were exposed to 5 μM αSYN for the indicated
amount of time, and then subjected to fractionation and
immunoblot analysis (Figure 1B (a) and (b), respectively).
The KG1C cells used in the present study were confirmed
to express oligodendroglial markers, including CNPase
and myelin basic protein [34]. Interestingly, only one mi-
nute after the addition of αSYN, monomeric αSYN (X1)
had been incorporated and then continued to increase
mainly in hydrophilic fraction. In parallel, the SDS-stable
dimeric/trimeric αSYN (X2-X3), as well as the multimers
and truncated fragments (arrow), also gradually appeared
in hydrophilic fraction. Similarly, a dose-dependent in-
crease in the intracellular monomeric and oligomeric
forms of αSYN was observed in the SH-SY5Y cells that
were exposed to different concentrations of recombinant
αSYN (0–10 μM) for 24 hours (Figure 1B (c)). To clearly
identify the high-molecular-weight (HMW) αSYN species,
the same blot was stripped and reprobed with the rabbit
polyclonal αSYN Ab (#2628, Cell Signaling Technology)
to eliminate the non-specific band detected by the anti-
synuclein-1 Ab (Figure 1B (d)). In addition, the amount of
monomeric αSYN in the hydrophilic fractions of exposed
cells was quantitatively measured by densitometric ana-
lysis (Additional file 1: Figure S1A (a)-(c). Similarly to the
untagged αSYN, the GST-αSYN added to the culture
medium was time-dependently incorporated into SH-
SY5Y cells and formed GST-immunopositive oligomers
and an HMW smear mainly in the hydrophilic fraction,
demonstrating that extracellular αSYN was internalized
and oligomerized in the exposed cells (Additional file 1:
Figure S1B). In mammals, the SYN family consists of three
members (α-,β-,γ-), and all SYN genes are well conserved
across species [35]. Importantly, we found that αSYN was
exclusively internalized into cells compared to β-synuclein
(βSYN) and γ-synuclein (γSYN). In addition, the familial
PD-linked A30P and A53T mutations of αSYN enhanced
the buildup of the SDS-stable HMW species when com-
pared to the wt-αSYN (Additional file 2: Figure S2). It is
important to note that αSYN (10 μM) exposure for up to
10 days did not result in any changes in the cellular
morphology or growth retardation (data not shown).
The formation of cytoplasmic inclusions in neuronal and
oligodendroglial cells exposed to α-synuclein
Immunocytochemistry showed that large perinuclear
inclusions, as well as small aggregates, were observed in
the SH-SY5Y and KG1C cells exposed to 5 μM recom-
binant αSYN for up to 24 hours. In both cell lines after
treatment, the αSYN-positive large inclusions and small
aggregates were positive for ubiquitin and thioflavin S
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Figure 1 (See legend on next page.)
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Figure 1 Extracellular α-synuclein is internalized and assembled into SDS-stable oligomers in neuronal and oligodendroglial cells. A,
The characterization of recombinant αSYN. (a) The expressed GST-αSYN and tag-free αSYN were analyzed by CBB staining and western blotting with
an anti-αSYN Ab (1 μg per lane). Upon IPTG induction, the transformed E. coli produced a GST-αSYN fusion protein that migrated at 44 kDa under
denaturing conditions (asterisk). Following the removal of the GST-tag, monomeric αSYN was detected, which corresponded to a molecular mass of
18 kDa (arrowhead). An immunoblot using an anti-GST antibody did not detect any GST-αSYN after the removal of the GST moiety. (b) In the native
condition, the absolute majority of recombinant αSYNmigrated to approximately 54 kDa, corresponding to trimeric (X3) αSYN as well as some
monomers (arrowhead) and oligomers (X2 and X4)/multimers. (c) Recombinant αSYN in cell-free culture medium did not self-assemble into SDS-stable
oligomers after 24 hours at 37°C. B, Extracellular αSYN was incorporated and assembled into oligomers in neuronal and oligodendroglial cells. SH-SY5Y
(a) and KG1C (b) cells were exposed to 5 μM αSYN for the indicated amount of time, and the cells were then subjected to fractionation and αSYN
immunoblot analysis (50 μg lysate per lane). Oneminute after the addition of αSYN, monomeric αSYN (X1) was incorporated, and the amount of αSYN
increased thereafter mainly in the hydrophilic fraction. In parallel, the SDS-resistant dimeric/trimeric αSYN (X2-X3), as well as the multimers and
truncated fragments (arrow), gradually appeared in the hydrophilic fractions. Hsp90 and Na+/K+ ATPase αwere used as markers for the cytosol and the
plasmamembrane, respectively. (c) A dose-dependent increase in intracellular monomeric (X1) and oligomeric (X2-X3) αSYN was observed mainly in
the hydrophilic fractions prepared from the cells exposed to varying concentrations of recombinant αSYN (0–10 μM) for 24 hours. An asterisk indicates
the non-specific band. Representative blots from three independent experiments are presented.
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immunostained for serine 129-phosphorylated αSYN in
both cells. Neither αSYN-positive inclusions nor small
aggregates were detected in control cells treated with
the column flow-through (Figure 2A (a) and (b)). The
spatial co-localization of ubiquitin and the αSYN-
positive inclusions was confirmed by orthogonal recon-
structions from confocal z-stacks in the xz- and yz-
planes. Furthermore, the double-immunolabeling studies,
depicted in Figure 2B (a) and (b), demonstrated that the
large juxtanuclear large inclusions were not only co-
localized with γ-tubulin and peripherin but were also
enveloped within a vimentin cage, suggesting that the mo-
lecular machinery controlling aggresomal formation may
contribute to their biogenesis [2]. Of note, the αSYN-
positive inclusion bodies in the KG1C cells were co-
localized with tubulin-polymerization-promoting protein/
p25α (TPPP/p25α), a known marker of GCI in the affected
brain lesions of MSA patients [34,36,37]. The formation of
αSYN-positive cytoplasmic inclusions was also confirmed
in primary rat cortical neurons treated under the same
condition, suggesting that these results were not a cell
line-specific phenomenon (Figure 2C). The percentage of
perinuclear inclusion-bearing SH-SY5Y and KG1C cells
increased in a time-dependent manner, reaching 35% and
24%, respectively, at 24 hours (Figure 2D).Lysosomal inhibition enhanced α-synuclein oligomer
formation and impaired autophagic flux
The αSYN-positive aggregates in the cells exposed to re-
combinant αSYN were partially co-localized with the
markers for early endosomes (Rab5A) and lysosomes
(Lamp-1) (Figure 3A). To confirm the role of the intact
lysosomal system in the degradation of incorporated
αSYN, SH-SY5Y cells were treated with the vacuolar H+
ATPase inhibitor bafilomycin A1 (0–5 nM) together
with 5 μM αSYN for 24 hours. Following the fraction-
ation process, all samples were analyzed by western blotanalysis (Figure 3B). As shown by the immunoblotting,
bafilomycin treatment increased the intracellular accu-
mulation of HMW αSYN oligomers in the hydrophilic
fraction of αSYN-exposed cells in a dose-dependent
manner. In contrast, bafilomycin treatment did not
affect the level of endogenous αSYN in the control cells
lacking αSYN exposure. In the αSYN-treated SH-SY5Y
cells, co-treatment with bafilomycin augmented the in-
duction of LC3-II protein, which is indicative of an
increase in macroautophagy and autophagosome forma-
tion. Under this condition, we could not detect caspase-3
cleavage, a hallmark of apoptosis (Figure 3C). Hence,
lysosomal inhibition impairs the autophagic flux in
αSYN-treated neuronal and oligodendroglial cells.The inhibition of dynamin GTPases decreased α-synuclein
internalization by neuronal and oligodendroglial cells
The internalization of αSYN oligomers is thought to be
mediated by endocytosis because K44A dynamin 1, a
dominant-negative mutant that blocks endocytic vesicle
formation, was previously shown to reduce the number of
incorporated αSYN aggregates in COS-7 cells and primary
astrocytes [21,38,39]. The enhanced endocytosis of pre-
formed fibrils of αSYN in response to the addition of
wheat germ agglutinin (WGA) was shown to increase the
extent of pathology in cultured neuronal cells [20]. Lee
and his colleagues have shown that monomeric αSYN can
be internalized into cells without endocytosis, whereas
aggregated forms enter cells via endocytosis [19,39]. Com-
plementarily, the inhibition of endocytosis decreased the
cellular uptake of αSYN in vitro and in vivo [22]. The in-
volvement of the endocytic process during αSYN
internalization is further supported by a previous prote-
omic analysis showing that microglial activation, second-
ary to the internalization of aggregated αSYN, requires
clathrin, which plays major roles in endocytosis and ves-
icular trafficking [40]. Of the three dynamin isoforms iden-
tified thus far, dynamin 1 and dynamin 2 are mainly
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Figure 2 The formation of cytoplasmic inclusions in neuronal and oligodendroglial cells exposed to α-synuclein. A, Large perikaryal
inclusions as well as small aggregates were observed in the SH-SY5Y (a) and KG1C (b) cells exposed to 5 μM recombinant αSYN for 24 hours. The
αSYN-positive inclusions and small aggregates were positive for ubiquitin and thioflavin S staining, whereas only the large inclusions co-
immunostained positively for phosphorylated serine 129-αSYN. Neither αSYN-positive inclusions nor small aggregates were detected in cells
treated with the column flow-through. The crossed lines indicate the positions of the xz- and yz-planes. B, Double-immunolabeling studies
demonstrated that the juxtanuclear large inclusions co-localized with γ-tubulin, peripherin, and/or vimentin, which are known markers of the
aggresome (a and b). The αSYN-positive inclusion bodies in the KG1C cells (b) were co-localized with TPPP/p25α, a known marker for GCI in
MSA. C, The formation of αSYN-positive cytoplasmic inclusions (arrowhead) was also confirmed in primary rat cortical neurons treated under the
same condition. No visible αSYN-positive inclusions were detected in the mock-treated cells. D, After αSYN exposure, the incidence of perinuclear
inclusions in both the SH-SY5Y and KG1C cells increased in a time-dependent manner, reaching 35% and 24%, respectively, at 24 hours. Data are
expressed as the mean± standard errors. The immunostaining was performed three times and exhibited consistent results. Scale bar: 10.0 μm.
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1 is highly expressed in the nervous system, whereas dyna-
min 2 is ubiquitously expressed in all tissues [42,43]. To
investigate the functional roles of dynamin GTPases in the
incorporation of αSYN, we examined the expression pro-
file of dynamin isoforms in neuronal and oligodendroglial
cells (Figure 4A). As shown by immunoblotting, dynamin
2 was widely expressed in both types of cells, whereas
dynamin 1 was strongly expressed only in the dopamin-
ergic neuronal cells. However, the expression of dynamin
1 was weak (MO3.13) or absent (KG1C) in cells of the
oligodendroglial lineage. It is known that several selective
serotonin reuptake inhibitors (SSRIs) also inhibit dynamin
GTPases, which suggests the influence of a class effect.
Among the dynamin inhibitors thus far examined, sertra-
line (ZoloftW), a second-generation SSRI, exhibited the
strongest effect against both dynamin 1 and 2 [41,43]. We
found that the pharmacological inhibition of dynamin
GTPase activity by sertraline treatment (50 mM stock in
DMSO with a working concentration of 0–10 μM, Sigma)
prevented αSYN uptake by SH-SY5Y and KG1C cells in a
dose-dependent manner (Figure 4B (a) and (b), respect-
ively). Both cells types were treated with 5 μM αSYN for
30 min with varying concentrations of sertraline as indi-
cated. Consistent with this result, the inhibition of dyna-
min 1 through the use of a K44A dominant-negative (DN)
mutant or small interference RNA (siRNA) resulted in a
considerable decrease in αSYN incorporation into SH-
SY5Ycells (Figure 4C (a) and (b), respectively). In addition,
both αSYN monomers and SDS-stable HMW oligomers
were increased in the cells overexpressing wild-type (wt)
dynamin 1. The control experiment, which was not
exposed to recombinant αSYN, demonstrated that dyna-
min 1 manipulation did not affect the expression level of
endogenous αSYN in the SH-SY5Ycells.
Sertraline treatment inhibited the neuron-to-neuron and
neuron-to-oligodendroglia transmission of α-synuclein in
co-culture models
To test whether sertraline could prevent the cell-to-cell
spread of αSYN, we performed co-culture experiments.
For this purpose, SH-SY5Y cells overexpressing N-terminalmCherry-tagged αSYN (donor cells) were co-cultured with
PC12 neuronal or MO3.13 oligodendroglial cells stably
expressing Enhanced Green Fluorescence Protein (EGFP,
acceptor cells), in the presence or absence of 10 μM sertra-
line. The mCherry fluorophore was used to trace the
donor-derived αSYN protein. After 72 hours of co-culture,
the transmission of mCherry-αSYN from the donor cells
to the acceptor PC12 and MO3.13 cells was detected, con-
firming the uptake of mCherry-αSYN secreted from donor
cells (Figure 5A). The spatial distribution detail of the
mCherry fluorescence in donor cells was confirmed by or-
thogonal reconstructions from confocal z-stacks in the xz-
and yz-planes. Co-culture experiments using donor cells
expressing mCherry-αSYN showed that the percentage of
acceptor cells with inclusions were 4.2% (PC12) and 3.8%
(MO3.13), which was much higher than the percentage of
the inclusion-positive cells (under 0.2% in both cell lines)
from the co-culture with mCherry-expressing donor cells
(Figure 5A and B). The addition of sertraline to the cul-
ture medium reduced the amount of incorporated
mCherry-αSYN in the acceptor cells, whereas this effect
was not observed in the acceptor cells co-cultured with
mCherry-expressing donor cells (Figure 5B). We con-
firmed that the sertraline treatment did not affect the
secretion of mCherry-αSYN from the donor SH-SY5Y
cells (Figure 5C). It should be noted that the extracellu-
lar mCherry-αSYN released into culture media seems to
be significantly lower than the recombinant αSYN used
in the previous experiments. We hypothesize that this is
the reason for the relatively low internalization of
mCherry-αSYN in the acceptor cells of co-cultures com-
pared to the level of inclusion formation in the cells
exposed to recombinant αSYN. Together, these results
suggest that the endocytic process contributes signifi-
cantly to the neuronal as well as oligodendroglial uptake
of αSYN.
Discussion
Although αSYN is generally located in the cytoplasm,
several studies have demonstrated that αSYN has an af-
finity for phospholipids and vesicles [44,45]. In addition,
αSYN is known to be delivered to the plasma membrane
A KG1C cellSH-SY5Y cell
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Figure 3 (See legend on next page.)
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Figure 3 Lysosomal inhibition facilitates α-synuclein oligomer formation and impairs autophagic flux. A, A portion of the αSYN-positive
aggregates found in the αSYN-treated SH-SY5Y cells (5 μM recombinant αSYN for 24 hours) showed partial co-localization with markers of early
endosomes (Rab5A) and lysosomes (Lamp-1). The crossed lines indicate the positions of the xz- and yz-planes. Immunostaining was performed
three times and exhibited consistent results. Size bar: 10.0 μm. B, Pretreatment of the cells with bafilomycin A1 (0–5 nM) increased the
intracellular accumulation of the αSYN oligomers (X2 and higher) in a dose-dependent manner. Furthermore, this increase was mainly observed
in the hydrophilic fractions of the αSYN-exposed cells, whereas the level of the αSYN monomer (X1) was unchanged. Fifty micrograms of lysates
were analyzed by immunoblotting and the blot was probed with an anti-αSYN Ab. Hsp90 and Na+/K+ ATPase α were used as markers for the
cytosol and the plasma membrane, respectively. The asterisk indicates the non-specific band. C, In the αSYN-exposed SH-SY5Y cells (5 μM
recombinant αSYN for 24 hours), bafilomycin (5 nM) treatment augmented the induction of the LC3-II protein, whereas no cleaved fragments of
caspase-3 were detected. Representative western blots from three independent experiments are presented.
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(ER)-Golgi secretory pathway [46]. Furthermore, increas-
ing evidence has suggested that nanomolar concentra-
tions of αSYN can be found in neuronal culture medium,
as well as in body fluids such as plasma and cerebro-
spinal fluid [47,48]. The secreted monomeric and oligo-
meric forms of αSYN were shown to re-enter
neighboring cells, resulting in various cytotoxic effects,
such as the production of reactive oxygen species, the
generation of a glial cell inflammatory response [18,21],
and synaptic malfunction [20]. In the present study, we
showed that, in cultured neuronal and oligodendroglial
cells, the incorporated αSYN oligomers were assembled
into SDS-stable HMW oligomers and could form LB-
and GCI-like cytoplasmic inclusions. Except for KG1C
cells, which do not express endogenous αSYN, it is pos-
sible that the internalized recombinant αSYN may be
entangled with endogenous αSYN, and the assembled
HMW oligomers in the SH-SY5Y neuronal cells may
consist of both endogenous and recombinant αSYN.
Consistent with a previous study, we confirmed that
most of the internalized αSYN was located within the
intracellular soluble fraction rather than the membrane
fraction, indicating that extracellular αSYN rapidly
crosses the cellular membrane [18]. Furthermore, wild-
type αSYN has been shown to be degraded by lysosomes
through chaperone-mediated autophagy, and decreased
lysosomal function has also been observed in PD patients
[49-52]. In agreement with this result, we detected inter-
nalized αSYN in the endosomal compartment, where it
was eventually degraded by the lysosomes. Our data
showed that lysosomal inhibition impairs the autophagic
flux in αSYN-treated neuronal and oligodendroglial cells.
This observation strongly suggests that proper lysosomal
machinery is required for the clearance of the incorpo-
rated αSYN oligomers and is therefore indispensable for
the maintenance of cellular homeostasis.
In addition to the Lewy pathology in PD, the presence of
oligodendrocytic αSYN deposition, i.e., GCI, in MSA has
attracted a significant amount of attention [29,53-55].
However, regarding the pathogenesis of MSA, it remains
unclear why αSYN accumulates in an oligodendrocytes,which do not normally express endogenous αSYN [28].
It is possible that αSYN expression may be upregulated
and/or inefficiently degraded in affected oligodendro-
cytes. Alternatively, it is plausible that oligodendrocytes
may actively take up αSYN molecules derived from neu-
rons. Indeed, endocytosis regulatory proteins such as
Rab5 and Rabaptin-5 are known constituents of GCIs
[56]. It is also possible that an intrinsic protein, such as
TPPP/p25α, may promote the aggregation of internalized
αSYN within oligodendroglia [34,57,58]. Interestingly, the
prion-like hypothesis supports the possibility that aber-
rant oligodendroglial expression of αSYN may have an
ectopic origin. Our study provides the first concrete evi-
dence that extracellular αSYN can be incorporated and
assembled into HMW oligomers and inclusions that
mimic GCIs in cultured oligodendrocytes. In protein-
folding diseases, protein misfolding and aggregation are
thought to follow a ‘seeding-nucleation’ mechanism
[59-61], whereby misfolded αSYN is transmitted from a
LB-bearing donor cell to a neighboring recipient cell
and can act as a template for the conversion of native,
unfolded αSYN into a β-sheet-rich conformation within
the recipient cell. However, given that cultured oligo-
dendroglial cells without inherent αSYN expression can
import extracellular αSYN and form HMW oligomers,
the existence of endogenous αSYN may not be a pre-
requisite for the buildup of αSYN aggregates in the re-
cipient cells.
The precise mechanisms by which the intercellular
transmission of αSYN occurs remain controversial. Lee
and colleagues implicated exocytosis as a plausible
mechanism for αSYN release from cultured neuronal
cells because its release was effectively blocked under
low-temperature conditions [39]. As brefeldin A, an in-
hibitor of ER-Golgi-dependent exocytosis, is ineffective
at preventing the secretion of nascent αSYN secretion
by MES cells, αSYN exocytosis is thought to rely on an
unconventional exocytic pathway [62]. Intriguingly, the
small GTPase Rab5, which is a known marker of early
endosomes, is critical for the endocytosis of exogenous
αSYN into neuronal cells [18]. In a yeast model, the






























































































































































































































































Figure 4 (See legend on next page.)
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Figure 4 The inhibition of dynamin GTPases decreases the internalization of α-synuclein by neuronal and oligodendroglial cells. A, The
expression profile of various dynamin isoforms across neuronal and oligodendroglial cells. Dynamin 2 was widely expressed in both types of cells,
whereas dynamin 1 was strongly expressed in dopaminergic neuronal cells. However, the expression of dynamin 1 was weak (MO3.13) or absent
(KG1C) in cells of the oligodendroglial lineage. Equal loading was confirmed using α-tubulin as control. B, The pharmacological inhibition of
dynamin GTPase activity via sertraline treatment (0–10 μM for 30 min) dose-dependently prevented both monomeric (arrowhead) and oligomeric
αSYN accumulation in SH-SY5Y (a) and KG1C (b) cells. Both cells were treated with 5 μM αSYN for 30 min with different concentrations of
sertraline, as indicated. The control cells were treated with solvent (0.1% DMSO) alone. Fifty micrograms of each lysate was analyzed by
immunoblotting, and the blot was probed with an anti-αSYN Ab. Hsp90 and Na+/K+ ATPase α were used as markers for the cytosol and the
plasma membrane, respectively. The asterisk indicates the non-specific band. C, Consistent with the results shown in Figure 4B, the inhibition of
dynamin 1 through the use of either the K44A DN mutant (a) or siRNA (b) resulted in a marked reduction of internalized αSYN in SH-SY5Y cells.
Cells were treated with 5 μM αSYN (for 30 min) 48 hours after either the DN-dynamin1 transfection or the siRNA silencing of dynamin 1. Note
that the αSYN monomer and the SDS-stable HMW oligomers were increased in cells overexpressing wild-type dynamin 1. Representative
immunoblots from three independent experiments are shown.
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which led to the budding of endocytic vesicles via
receptor-mediated endocytosis and the subsequent tar-
geting of this form of αSYN to the vacuole for degrad-
ation [63]. Furthermore, previous studies by our lab and
others have demonstrated that internalized αSYN is
secreted from neurons via a process that is modulated
by the recycling endosome regulator Rab11a [64,65]. In
the case of prion disease, both the normal cellular prion
protein (PrPc) and the abnormally folded pathogenic
form (PrPsc) are associated with nanovesicles called
‘exosomes’ that are released from non-neuronal and
neuronal cells [66,67]. However, the involvement of the
exosomal vesicle in αSYN secretion remains unclear.
αSYN has been shown to be secreted by the exosome,
and exosome-containing conditioned medium can in-
duce neuronal cell death [68,69]. In contrast, we recently
demonstrated that extracellular αSYN was mainly
detected in the supernatant fraction rather than in the
exosome-containing pellets obtained from neuronal cul-
ture medium or CSF [64]. Moreover, we found that the
perturbation of exosome formation by a DN mutant of
vacuolar protein sorting 4 (VPS4) not only interfered
with lysosomal targeting of αSYN but also facilitated
αSYN secretion [64].
Regardless of the mechanisms involved in αSYN secre-
tion, there is evidence to support the uptake of extracel-
lular αSYN by neighboring cells, which subsequently
facilitates aggregate formation. Previous reports have
suggested that the internalization of αSYN oligomers
may be mediated by the endocytic process; the overex-
pression of a DN-dynamin effectively reduced the extent
of incorporated αSYN aggregates in cultured cell lines
[21,39]. Furthermore, the inhibition of endocytosis by
monodansylcadaverine and dynasore has also been
shown to decrease αSYN uptake both in vitro and
in vivo [22]. Coincubation of αSYN pre-formed fibrils
with WGA enhances the αSYN pathology in neuronal
cells, indicating adsorptive-mediated endocytosis as the
potential mechanism of αSYN internalization [20]. Theimportance of the endocytic process in the uptake of
extracellular αSYN is further supported by our findings
showing that genetic as well as pharmacological disrup-
tion of the dynamin GTPases through the administration
of sertraline, a widely used antidepressant, significantly
decreased the internalization and translocation of αSYN.
It should also be noted that the concentration of sertra-
line used in our study (10 μM=3 μg/ml) is comparable
to the concentrations observed to be therapeutically
effective within the CSF and brain (2 μg/ml) for its anti-
depressant effects [70]. In fact, neuropsychiatric manifes-
tations such as depression, apathy, and anxiety are
frequently encountered as non-motor symptoms in PD
patients [71,72]. SSRIs are currently used as a first-line
therapy for PD-associated depression [73]. Thus, the
identification of novel therapeutic uses for sertraline not
only provides a strategy focused on the prevention of
the pathological propagation of αSYN but also has the
advantage of utilizing time-tested drugs for the benefit
of patients. A recent study has shown that the first SSRI,
fluoxetine, ameliorated behavioral and neuropathological
deficits in an MSA mouse model [74]. They concluded
that the protective effect of fluoxetine might be attribu-
ted to the increased level of neurotrophic factors and/or
the activation of the ERK signaling pathway; however,
the reduction of αSYN-propagation through the inhib-
ition of dynamin may be another underlying mechanism.
Indeed, tricyclic antidepressants, which are also known
to inhibit dynamin GTPases, have been shown to slow
disease progression in PD [41,75]. In the case of MSA, a
German group has reported the effectiveness of paroxe-
tine in a small, short-term trial with 19 MSA patients
[76]. In this study, motor disabilities and dysarthria were
significantly improved compared with the placebo group.
It is also interesting to note that paroxetine may prevent
the glottis stenosis in MSA patients [77]. Further investi-
gations with larger samples are necessary to assess the
long-term safety and effectiveness of SSRI treatment in
MSA. We are currently awaiting for the outcome of a











































































































































Figure 5 Sertraline inhibits the neuron-to-neuron and neuron-to-oligodendroglia transmission of α-synuclein in co-culture models. A,
SH-SY5Y cells overexpressing mCherry or N-terminally mCherry-tagged αSYN (donor cells) were co-cultured with PC12 neuronal or MO3.13
oligodendroglial cells stably expressing EGFP (acceptor cells) in the presence or absence of 10 μM sertraline. Vehicle-only-transfected cells were
treated with solvent (0.1% DMSO) only. The mCherry fluorophore was used to trace the donor-derived αSYN protein. After 72 hours of co-culture,
the transmission of mCherry-αSYN from the donor cells to the acceptor PC12 as well as MO3.13 cells was detected, confirming the uptake of
mCherry-αSYN secreted from the donor cells. The arrowhead indicates the transferred mCherry-αSYN-positive aggregates in the acceptor cells.
The crossed lines indicate the positions of the xz- and yz-planes. B, A co-culture experiment using donor cells expressing mCherry-αSYN showed
that the percentage of acceptor cells with inclusions were 4.2% (PC12) and 3.8% (MO3.13), which is much higher than the percentage of
inclusion-positive cells (under 0.2% in both cell lines) co-cultured with mCherry-expressing donor cells. The addition of sertraline to the culture
medium reduced the incorporation of mCherry-αSYN into the acceptor cells (*p< 0.05), whereas this effect was not observed in the acceptor cells
that were co-cultured with the mCherry-expressing donor cells. To quantify the mCherry-positive inclusions in the acceptor cells, the total
number of cells containing aggregates was counted per 250–300 cells within five randomly selected fields. From this value, the percentages of
cells with red-fluorescent inclusions were calculated. Pooled data from four independent experiments were statistically analyzed. Data are
presented as the mean± standard errors. C, Western blot analysis demonstrated that sertraline treatment did not affect the secretion of the
mCherry-αSYN from the donor SH-SY5Y cells. BSA and Hsp90 were used as markers of the culture medium and the cytosolic proteins,
respectively. Each immunoblot was performed at least three times and the replicates yielded similar results.
Konno et al. Molecular Neurodegeneration 2012, 7:38 Page 11 of 16
http://www.molecularneurodegeneration.com/content/7/1/38
Konno et al. Molecular Neurodegeneration 2012, 7:38 Page 12 of 16
http://www.molecularneurodegeneration.com/content/7/1/38treatment of MSA (MSA-Fluox) being conducted in
France [78].
In summary, we demonstrated that αSYN was taken
up by neuronal and oligodendroglial cells, assembled
into HMW oligomers, and formed cytoplasmic inclu-
sions. Furthermore, we have provided evidence that
αSYN uptake by neuronal and oligodendroglial cells is
regulated by dynamin GTPases, which implies a role
for the endocytic process in this activity. The import-
ance of the vesicular trafficking machinery in the patho-
genesis of PD is also highlighted by recent findings that
a mutation in the VPS35 gene, which encodes a retro-
mer complex involved in the retrograde transport of
proteins from the endosome to the trans-Golgi net-
work, can cause late-onset familial PD [79-81]. Further-
more, the prevention of αSYN-mediated pathology by
sertraline is a potentially promising method for the
treatment of PD and other synucleinopathies. Thus, de-
fining the precise mode of intercellular αSYN transmis-
sion will shed light on the pathogenic mechanisms
involved in synucleinopathies, and this research may
pave the way for the identification of novel targets for
therapeutic intervention in other neurodegenerative
diseases.
Methods
Plasmid construction and preparation
For the bacterial expression of the GST-αSYN fusion
protein, human αSYN cDNA was subcloned into the
SalI and NotI restriction sites of the pGEX6P-1 vector
(GE Healthcare Life Sciences, Piscataway, NJ), which
encodes an N-terminal GST fusion tag that is cleavable
by a human rhinovirus 3C proteinase recognition site
(Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro, referred to as the
PreScissionW site). An N-terminal mCherry-tagged
human wt-αSYN cDNA was introduced into the KpnI
and XhoI sites of the pcDNA3.1+ expression vector (Life
Technologies/Invitrogen, Carlsbad, CA). The pEGFP-C1
eukaryotic expression plasmids (Clontech, Mountain
View, CA) encoding the EGFP-tagged human wt and
DN mutant K44A dynamin 1 were kindly provided by
Dr. Hiroshi Miyoshi at the St. Marianna University
School of Medicine in Kawasaki, Japan. Plasmid DNA
used for transfection was prepared with the Genopure
Plasmid Maxi Kit (Roche, Basel, Switzerland). The fidel-
ity and orientation of the expression constructs were
confirmed by restriction digestion and nucleotide se-
quencing analyses.
Recombinant α-synuclein purification
The GST-αSYN fusion construct (pGEX6P-1/αSYN) was
transformed into the BL21(DE3)pLysS E. coli strain for
protein expression. The transformed bacteria were
grown in LB medium containing 100 μg/ml ampicillinand 35 μg/ml chloramphenicol (for pLysS) at 37°C until
reaching an A600 of 0.4. The bacteria were then cultured
for an additional 5 hours following induction with
0.5 mM IPTG. The bacteria were harvested by centrifu-
gation, resuspended in ice-cold PBS (pH 7.4), and dis-
rupted by ultrasonication (Smurt NR-50, Microtec,
Chiba, Japan). After removal of the cell debris, the
supernatant was loaded onto a glutathione-Sepharose 4B
column (GE Healthcare) equilibrated with PBS. The
GST-αSYN fusion protein was washed with PBS three
times and was then eluted with 10 mM glutathione elu-
tion buffer. The final eluate that flowed through the col-
umn was collected as the control specimen and was
further dialyzed against PBS overnight. Next, the GST
tag was cleaved overnight at 4°C on a carousel in the
presence of the PreScissionW protease (2 units for
100 μg fusion protein, GE Healthcare). After cleavage,
the sample was re-loaded onto the glutathione-
Sepharose 4B column, and the flowthrough containing
the tag-free αSYN was collected. The purity and the
identity of the recombinant αSYN were verified by
CBB staining and western blot analysis. The recom-
binant βSYN and γSYN, as well as A30P and A53T
mutants of αSYN, were purchased from ATGen Co., Ltd.
(Gyeonggi-do, Korea).
Cell culture and plasmid transfection
Dopaminergic neuronal cells (human SH-SY5Y and rat
PC12) and human cells of oligodendroglia-lineage
(KG1C and MO3.13) were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM; Life Technologies/
GIBCO, Carlsbad, CA) containing 4.5 g/l glucose,
2 mM L-glutamine (Life Technologies) and 10% FBS
(PAA Laboratories, Pasching, Austria) at a temperature
of 37°C under conditions of humidified 5% CO2/air. The
SH-SY5Y cells were purchased from American Type
Culture Collection (ATCC, Vienna, VA). The PC12 cells
were kindly given to us by Dr. Katsutoshi Furukawa, De-
partment of Geriatrics and Gerontology, Tohoku Univer-
sity, Sendai, Japan. The KG1C and MO3.13 cells were
purchased from RIKEN Cell Bank (Tsukuba, Japan) and
Cosmo Bio (Tokyo, Japan), Respectively. Plasmid DNAs
(2 μg DNA for 1.5X106 cells) were introduced into the
SH-SY5Y cells using the 4D-NucleofectorTM device with
the CA-137 program (LONZA AG, Cologne, Germany).
The cells were harvested 48 hours post-transfection un-
less otherwise stated. For the suppression of dynamin
GTPases, cells were treated with 5 μM αSYN for 30 min
with varying concentration of sertraline as indicated.
Likewise, the SH-SY5Y cells were treated with 5 μM
αSYN (for 30 min) 48 hours after transfection with the
DN-dynamin1 or the siRNA silencing of dynamin 1.
Stable transfection of mcherry-αSYN or EGFP in the
cultured cells was achieved using the FuGENE HDW
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turer’s instructions. For the stable transfection of
mcherry-αSYN or EGFP, the transfected cells were main-
tained under selective pressure with 300 μg/ml G418
sulfate (InvivoGen, San Diego, CA).
Primary cortical neuron culture
Primary cultures of rat cortical neurons were prepared
according to a previous method, with slight modifica-
tions [82]. The dissociated cortical neurons were plated
at a density of 0.5 × 106 cells on a poly-D-lysine-coated
disc (Sumilon Celldesk LF, Sumitomo Bakelite Co., Ltd.,
Tokyo, Japan) in a 24-well plate and cultured in Neuro-
basal A (Life Technologies/GIBCO) medium supplemen-
ted with 2% B27 (Life Technologies/GIBCO), 25 mM
glutamate, 18 mM glucose and 0.5 mM L-glutamine.
Half of the culture medium was replaced with fresh
medium excluding glutamate every 3 days. Six days after
the initiation of the culture, cells were exposed to 5 μM
recombinant αSYN for 24 hours and were then sub-
jected to immunocytochemical analysis.
siRNA knockdown of endogenous dynamin in SH-SY5Y cells
To suppress endogenous dynamin 1 expression in cul-
tured neuronal cells, siRNA specifically targeting human
dynamin 1 (sc-43737) was used; this specific siRNA and
a scrambled control siRNA (sc-36869) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). SH-
SY5Y cells in log-phase growth were nucleofected with
target-specific or control-scrambled siRNAs (300 nM for
2 × 106 cells) using the 4D-Nucleofector device with the
CA-137 program and SF solution (LONZA AG).
Seventy-two hours after gene silencing, the cells were
harvested and subjected to further studies.
Co-culture experiments
For the mixed culture of αSYN donor and acceptor cells,
SH-SY5Y neuronal cells overexpressing mCherry or
mCherry-tagged αSYN (2 × 105 donor cells in a 3.5-cm
dish) were co-cultured with neuronal PC12 or oligo-
dendroglial MO3.13 cells stably expressing EGFP
(2 × 105 acceptor cells in a 3.5-cm dish) in culture
medium with or without 10 μM sertraline for 5 days.
Incorporated mCherry-αSYN in the acceptor cells was
evaluated using a FluoViewTM FV300 confocal microscope
system equipped with HeNe-Green (543 nm) and Ar
(488 nm) laser units (Olympus, Tokyo, Japan). To quan-
tify the mCherry-positive cytoplasmic inclusions in the
acceptor cells, the total number of cells containing
aggregates was counted per 250–300 cells from each of
five randomly selected fields. From this, the percentages
of cells with red-fluorescent inclusions were calculated.
Data pooled from four independent experiments were
statistically analyzed with the Student's t-test. The datawere presented as the mean ± standard errors. For the
double labeling experiments, the images were collected
using a single excitation for each wavelength individually
and were then merged using Fluoview image analyzing
software (version 4.1, Olympus).
Cell fractionation and western immunoblot analysis
Mechanically harvested cells were washed twice with
ice-cold PBS. Next, the hydrophobic membrane fraction
and hydrophilic fraction were prepared using the
Mem-PERW Eukaryotic Membrane Protein Extraction
Reagent kit (Thermo Scientific, Waltham, MA) according
to the manufacturer’s instructions. In some experiments,
the cells were pretreated with bafilomycin A1 (0–5 nM for
24 hours) or sertraline (0–10 μM for 30 min) with or with-
out exposure to αSYN. Successful separation of the hydro-
philic fraction from the membrane fraction was verified by
immunoblot analyses using Abs against the cytosolic
Hsp90 and the plasma membrane localized protein
Na+/K+ ATPase α, respectively. In some experiments, cells
were directly solubilized in radio-immunoprecipitation
assay (RIPA) buffer (1% NP-40, 0.5% deoxycholate, 0.1%
SDS, 1 mM EDTA, 10 mM sodium pyrophosphate, 50 mM
sodium fluoride, 1 mM sodium orthovanadate, 150 mM so-
dium chloride, 50 mM Tris–HCl (pH 8.0) plus 1x
CømpleteW protease inhibitor cocktail; Roche). Samples
containing 50 μg total protein were electrophoresed on
SDS-polyacrylamide gels (12.5%) and transferred onto poly-
vinylidene difluoride (PVDF) membranes (Immobilon-P;
Merck Millipore, Billerica, MA). Native-PAGE was per-
formed on 10-20% polyacrylamide gradient gels, according
to the standard protocol. In some experiments, the sepa-
rated proteins were visualized by staining with CBB R-250
(MP Biomedicals, Solon, OH). After blocking with 5% (w/v)
nonfat dry milk (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) in Tris-buffered saline with 0.1% Tween 20
(TBST), the membranes were incubated with the following
Abs: anti-synuclein-1 (63320, 1:1000; BD Bioscience, San
Jose, CA), anti-αSYN (#2628, 1:1000; CST, Danvers, MA),
anti-GST (#2625, 1:1000: CST), anti-LC3 (PM036, 1:1000;
MBL, Nagoya, Japan), anti-caspase 3 (H-277, 1:2000; Santa
Cruz), anti-cleaved caspase 3 (Asp 175, 1:1000; CST), anti-
dynamin 1 (3G4B6, 1:1000; CST), anti-dynamin 2 (610263,
1:4000; BD Transduction Lab, Franklin Lakes, NJ), anti-
dopa decarboxylase (DDC) (AB1569, 1:1000; Millipore),
anti-TPPP/p25α (EPR3315, 1:1000; Epitomics, Burlingame,
CA), anti-GFP (M048-3, 1:2000;MBL) anti-Na+/K+ ATPase
α (D154-3, 1:20000; MBL), anti-Hsp90 (AC88, 1:2000;
Stressgen, Farmingdale, NY), anti-α-tubulin (clone DM1,
1:1000; Sigma) and anti-mCherry (5993, 1:1000; BioVision,
Mountain View, CA). The primary antibody labeling was
followed by the addition of HRP-conjugated secondary Abs
(1:10000; Jackson ImmunoResearch, West Grove, PA). The
bands were visualized with the LuminataTM Forte Western
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using the LAS-3000 mini image analyzer (Fujifilm, Tokyo,
Japan). Immunoblotting was performed at least three times.
In some experiments, the blots were scanned and densito-
metric analyses were performed using Image J (http://www.
rsb.info.nih.gov/ij/) [83]. The intensity unit of the αSYN
monomer was divided by that of Hsp90. Data are expressed
as the mean± standard errors.
Immunofluorescence confocal microscopy
Cells were fixed in 4% (w/v) paraformaldehyde in PBS
for 30 min and then permeabilized with 0.5% Triton
X-100 in PBS for 5 min. After blocking with 3% normal
goat serum (Wako Pure Chemical Industries) in PBS
for 30 min, the cells were incubated with the fol-
lowing primary antibodies: anti-synuclein-1 (1:1000;
BD Bioscience), anti-αSYN (#2628, 1:2000; CST),
anti-Serine 129 phospho-αSYN (EP1526Y, 1:1000; Epi-
tomics), anti-γ-tubulin (GTU-88, 1:4000; Sigma, St.
Louis, MO), anti-peripherin (AB1530, 1:1000; Milli-
pore-Chemicon), anti-vimentin (V9, 1:500; Sigma),
anti-ubiquitin (P4D1, 1:1000; Santa Cruz), anti-MAP2
(#4542, 1:1000; CST), anti-TPPP/p25 (EPR-3315, 1:1000;
Epitomics), anti-Rab5A Ab (S-19, 1:1000; Santa Cruz)
and anti-Lamp-1 (H4A3, 1:1000; DSHB, University of
Iowa, USA). For thioflavin S staining, the coverslips were
immersed in 0.03% (w/v) thioflavin S (Sigma) solution for
5 min and were then extensively washed with 70% etha-
nol. Positive immunostaining was detected after a 1-hour
incubation with Alexa 488- and Alexa 568-conjugated
secondary Abs (1:4000; Life Technologies/Molecular
Probes, Carlsbad, CA). Nuclei were counterstained with
TO-PRO3 iodide (1:1000; Molecular Probes) and were
pseudocolored in blue. The fluorescent images were ana-
lyzed with the FluoView FV300 confocal laser scanning
microscope system (Olympus). The crossed lines indicate
the positions of the xz- and yz-planes. To quantify the
αSYN-immunopositive inclusions, the total number of
cells with any aggregates was counted across 250–300
cells in five randomly chosen fields. From this, the per-
centages of cells with inclusions were calculated. Pooled
data from four independent experiments were statisti-
cally analyzed using the Student's t-test. The data are
expressed as the mean± standard errors.
Additional files
Additional file 1: Figure S1. Analyses of internalized α-synuclein
monomer in exposed cells. A, The densitometric analysis of monomeric
αSYN in hydrophilic fraction prepared from αSYN-exposed SH-SY5Y (a
and c) and KG1C cells (b). The intensity units of the αSYN monomer were
normalized by dividing them by that of Hsp90. Data are expressed as the
mean± standard errors. B, The GST-tagged αSYN (5 μM) in the culture
medium was time-dependently detected and shown to form HMW GST-
immunopositive oligomers and the HMW smear mainly in the
hydrophilic fraction of the SH-SY5Y cells, demonstrating that theextracellular αSYN was internalized and oligomerized in the exposed
cells. All immunoblottings were performed four times.
Additional file 2: Figure S2. The difference in α-synuclein
internalization behavior among mammalian synuclein-family proteins. To
evaluate the difference in the internalization behavior among the
synuclein-family proteins, SH-SY5Y cells exposed to 5 μM α-, β- and γ-
SYN, were fractionated and subjected to immunoblot analyses (right
panel). Note that αSYN was exclusively internalized into the SH-SY5Y cells,
whereas β- and γ-SYN were not. Furthermore, the A30P and A53T
mutations in αSYN strongly augmented the formation of the SDS-stable
oligomers in the hydrophilic fraction when compared to those observed
in the wt-αSYN-exposed cells. The specificity and sensitivity of each
synuclein Ab were verified by immunoblotting using the lysates of
HEK293T cells overexpressing Myc-tagged α-, β- and γ-SYN, respectively
(left panel). Representative immunoblots from three independent
experiments are shown.
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